Samsung BioLogics, Bristol Extend Drug-Production Agreement
This article was originally published in PharmAsia News
Samsung BioLogics and Bristol-Myers Squibb have agreed to extend their partnership that has the South Korea company producing several BMS biologic treatments.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.